Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Recruiting · NCT06809140 · Registry updated 2026-08-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer | Muscle Invasive Bladder Urothelial Carcinoma | Recruiting | Phase 2 | 2026-08-05 | NCT06809140 |
5 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Astellas Pharma Inc | 43 |
| Icahn School of Medicine at Mount Sinai | 256 |
| Matthew Galsky | 2 |
| Merck Sharp & Dohme LLC | 650 |
| Seagen Inc. | 31 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope | Duarte | United States | 238 |
| Columbia University Irving Medical Center | New York | United States | 234 |
| Fox Chase Cancer Center | Philadelphia | United States | 259 |
| Icahn School of Medicine at Mount Sinai | New York | United States | 342 |
| Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis | United States | 38 |